Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Louise F Dow

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Medicinal Chemistry|April 9, 2026
The Nitazene Era: A Critical Turning Point in the Synthetic Opioid Crisis Beyond FentanylLouise F Dow, Akinwunmi A Abisogun, Tomayo I Berida, et al.
RSC Medicinal Chemistry|December 2, 2024
Synthesis and biological characterization of a 17β hydroxysteroid dehydrogenase type 10 (17β-HSD10) inhibitorLouise F Dow, Rasangi Pathirage, Helen E Erickson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 16, 2024
<i>In vitro</i> ADME, mouse pharmacokinetics of LD14b, and bioanalysis of a novel aβ 17β-HSD10 modulator for the treatment of Alzheimer's diseaseSohel Daria, Devendra Kumar, Nagsen Gautam, et al.
RSC Medicinal Chemistry|November 17, 2023
The evolution of small molecule enzyme activatorsLouise F Dow, Alfie M Case, Megan P Paustian, et al.
ACS Chemical Neuroscience|July 8, 2022
Functionalized Allopurinols Targeting Amyloid-Binding Alcohol Dehydrogenase Rescue Aβ-Induced Mitochondrial DysfunctionAhmed Morsy, Krishnaiah Maddeboina, Ju Gao, et al.
Communications Chemistry|April 29, 2024
Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degraderAngelica V Carmona, Shirisha Jonnalagadda, Alfie M Case, et al.
Chemmedchem|July 8, 2024
Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 InhibitorsSravan K Jonnalagadda, Ling Duan, Louise F Dow, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Medicinal Chemistry|April 9, 2026
The Nitazene Era: A Critical Turning Point in the Synthetic Opioid Crisis Beyond FentanylLouise F Dow, Akinwunmi A Abisogun, Tomayo I Berida, et al.
RSC Medicinal Chemistry|December 2, 2024
Synthesis and biological characterization of a 17β hydroxysteroid dehydrogenase type 10 (17β-HSD10) inhibitorLouise F Dow, Rasangi Pathirage, Helen E Erickson, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|September 16, 2024
<i>In vitro</i> ADME, mouse pharmacokinetics of LD14b, and bioanalysis of a novel aβ 17β-HSD10 modulator for the treatment of Alzheimer's diseaseSohel Daria, Devendra Kumar, Nagsen Gautam, et al.
RSC Medicinal Chemistry|November 17, 2023
The evolution of small molecule enzyme activatorsLouise F Dow, Alfie M Case, Megan P Paustian, et al.
ACS Chemical Neuroscience|July 8, 2022
Functionalized Allopurinols Targeting Amyloid-Binding Alcohol Dehydrogenase Rescue Aβ-Induced Mitochondrial DysfunctionAhmed Morsy, Krishnaiah Maddeboina, Ju Gao, et al.
Communications Chemistry|April 29, 2024
Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degraderAngelica V Carmona, Shirisha Jonnalagadda, Alfie M Case, et al.
Chemmedchem|July 8, 2024
Coumarin-Based Aldo-Keto Reductase Family 1C (AKR1C) 2 and 3 InhibitorsSravan K Jonnalagadda, Ling Duan, Louise F Dow, et al.
Pageof 1